Poor
Not Aligned
Patient Risk:
Moderate
Summary
Some safety claims about benzodiazepine dependence/withdrawal and opioid co-use align with the provided label excerpts for alprazolam XR; however, many other claims (indications, dosing strengths/manufacturers/patents/therapeutic alternatives/FDA assurances/side effects/precautions) are not supported by the supplied prescribing information excerpts and some concern the wrong formulation (Xanax vs alprazolam XR).
Category Scores
Accurate Statements
Alprazolam is a benzodiazepine.
Unsupported by the provided excerpts; categorization as benzodiazepine is implied by provided label sections referring to benzodiazepines including alprazolam XR (SEC 5.1/5.2/5.3), but the excerpt text is not explicit that alprazolam itself is a benzodiazepine beyond 'benzodiazepines, including alprazolam XR'.
Alprazolam carries risks of dependence.
Supported (SEC 5.3: physical dependence; continued use may lead to physical dependence).
Alprazolam carries risks of addiction.
Supported (SEC 5.2: abuse, misuse, and addiction).
Alprazolam can cause withdrawal symptoms upon discontinuation.
Supported (SEC 5.3: withdrawal reactions; acute withdrawal reactions; protracted withdrawal syndrome).
The FDA ensures that generic drugs are bioequivalent to their brand-name counterparts.
Not supported by the provided excerpts.
The FDA ensures that generic drugs meet quality and manufacturing standards.
Not supported by the provided excerpts.
Unsupported Statements
Mylan manufactures alprazolam 1 mg tablets.
No manufacturer-specific or product-specific manufacturing claims are present in the supplied label excerpts.
Mylan alprazolam 1 mg tablets are a generic version of Xanax.
No generic-to-brand equivalence statement is present in the supplied excerpts.
Alprazolam tablets are prescribed for the treatment of anxiety disorders.
No indication text for anxiety disorders is present in the supplied excerpts.
Alprazolam tablets are prescribed for the treatment of panic disorder.
No indication text for panic disorder is present in the supplied excerpts.
Mylan produces alprazolam in strengths including 0.25 mg, 0.5 mg, 1 mg, 2 mg, and 3 mg tablets.
No formulation/strength dosing table is present in the supplied excerpts.
The primary patents for alprazolam have expired.
No patent status information is present in the supplied excerpts.
Because alprazolam patents have expired, generic versions are widely available from multiple manufacturers.
No patent/market availability statements are present in the supplied excerpts.
Generic alprazolam is required to meet the same standards for safety, efficacy, and quality as brand-name Xanax.
No regulatory standard comparison statements are present in the supplied excerpts.
The active ingredient, alprazolam, is identical in generic alprazolam and brand-name Xanax.
No brand vs generic composition/equivalence statement is present in the supplied excerpts.
Differences between generic alprazolam and Xanax may lie in inactive ingredients.
No generic vs brand excipient discussion is present in the supplied excerpts.
Differences in inactive ingredients can sometimes affect how a patient tolerates the medication.
No excipient-related tolerability statements are present in the supplied excerpts.
Alprazolam is a benzodiazepine.
The excerpts refer to 'benzodiazepines, including alprazolam XR' but do not explicitly state 'alprazolam is a benzodiazepine' as a standalone statement.
Common side effects of alprazolam include drowsiness.
No side effect list including drowsiness is present in the supplied excerpts.
Common side effects of alprazolam include dizziness.
No side effect list including dizziness is present in the supplied excerpts.
Common side effects of alprazolam include cognitive impairment.
No side effect list including cognitive impairment is present in the supplied excerpts.
Alprazolam should be used cautiously in elderly patients.
No geriatric caution statements are present in the supplied excerpts.
Alprazolam should be used cautiously in patients with a history of substance abuse.
The excerpts discuss assessing risk for abuse/misuse/addiction generally, but do not specifically state 'history of substance abuse' as a caution category.
Numerous pharmaceutical companies manufacture generic alprazolam.
No manufacturer list or statement is present in the supplied excerpts.
Teva Pharmaceuticals manufactures generic alprazolam.
No manufacturer-specific statement is present in the supplied excerpts.
Accord Healthcare manufactures generic alprazolam.
No manufacturer-specific statement is present in the supplied excerpts.
Aurobindo Pharma manufactures generic alprazolam.
No manufacturer-specific statement is present in the supplied excerpts.
For anxiety disorders, treatment often involves a combination of therapy and medication.
No treatment-combination statements are present in the supplied excerpts.
Alternative medications for anxiety include selective serotonin reuptake inhibitors (SSRIs).
No alternative medication class discussion is present in the supplied excerpts.
Alternative medications for anxiety include serotonin-norepinephrine reuptake inhibitors (SNRIs).
No alternative medication class discussion is present in the supplied excerpts.
Buspirone is a non-benzodiazepine option for anxiety.
No alternative therapies/discussion is present in the supplied excerpts.
Cognitive-behavioral therapy (CBT) is also a key component of treatment for anxiety.
No psychotherapy guidance is present in the supplied excerpts.
Mylan's alprazolam is regulated by the Food and Drug Administration (FDA).
No regulatory statement about Mylan specifically is present in the supplied excerpts.
The FDA ensures that generic drugs are bioequivalent to their brand-name counterparts.
No FDA generic bioequivalence statement is present in the supplied excerpts.
The FDA ensures that generic drugs meet quality and manufacturing standards.
No FDA generic quality/manufacturing statement is present in the supplied excerpts.
Contradictions
Low
AI Statement
Alprazolam XR extended-release tablets are generic versions of Xanax (brand-name).
Label Reference
Not evaluated: no brand/generic comparison content provided in the excerpts.
Important Omissions
Opioid co-use/respiratory depression boxed warning details: reservation of concomitant prescribing, lowest effective dose/minimum duration, and patient/caregiver counseling; none of these are present in the provided claim list.
Importance:
Moderate
Discontinuation guidance (gradual taper details, dose reduction limits) and contraindications specific to hypersensitivity and strong CYP3A inhibitors are not mentioned.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
While some dependence/withdrawal and addiction-related risks are consistent with the provided label excerpts, many other safety-relevant statements (exact opioid co-use warning content, contraindications, and discontinuation/taper instructions) are omitted or not supported by the supplied excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
High |
Recommendation
Not Aligned
Primary Issue
Most claims are not supported by the provided alprazolam XR prescribing-information excerpts (many are about manufacturers, patent status, generic equivalence, indications, side effects, and FDA/general health guidance).
Suggested Improvement
Restrict claims to the provided on-label excerpt content (e.g., SEC 5.1–5.3 opioid co-use and dependence/withdrawal/addiction risks) and avoid unsupported manufacturer/patent/FDA/generic-equivalence/indication/side-effect specificity unless the corresponding label sections are supplied.